文献速递免疫规划传染病防控与疫情报告

AZD1222(ChAdOx1 nCoV-19)基础免疫系列对SARS-CoV-2关注变异株的效力:南非成人随机安慰剂对照1b/2期研究(COV005)最终分析

Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005).
PubMed 文献 · Vaccine · 2023-04-27

COV005是一项在南非18-65岁成人中开展的多中心、双盲、随机、安慰剂对照1b/2期研究,最终分析评估AZD1222基础免疫系列对SARS-CoV-2关注变异株的效力和安全性。对无症状和有症状感染的效力分别为野生型90.6%、Beta变异株6.7%、Delta变异株77.1%,揭盲前未记录到重症COVID-19病例,安全性结果与中期分析一致。

要点

  • 对无症状和有症状感染的效力:野生型90.6%,Beta变异株6.7%,Delta变异株77.1%。
  • 揭盲前未记录到重症COVID-19病例。
  • 安全性结果与中期分析一致,未发现新的安全性问题。

核心结论

  • AZD1222基础免疫系列对野生型和Delta变异株的效力较高,对Beta变异株的效力较低。
  • 南非Delta波发生在基础免疫系列接种后≥9个月,提示基础免疫系列AZD1222接种可提供较好的保护持久性,可能源于回忆应答。

研究设计与样本

  • COV005是一项1b/2期、多中心、双盲、随机、安慰剂对照研究,在南非18-65岁成人中评估AZD1222(ChAdOx1 nCoV-19)基础免疫系列接种。
  • 临床试验注册号:CT.gov NCT04444674。

主要发现

  • 对无症状和有症状感染的效力:野生型90.6%,Beta变异株6.7%,Delta变异株77.1%。
  • 揭盲前未记录到重症COVID-19病例。
  • 安全性结果与中期分析一致,未发现新的安全性问题。

关键数值与推荐

  • 对无症状和有症状感染的效力:野生型90.6%,Beta变异株6.7%,Delta变异株77.1%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

COVID-19 vaccine efficacy (VE) has been observed to vary against antigenically distinct SARS-CoV-2 variants of concern (VoC). Here we report the final analysis of VE and safety from COV005: a phase 1b/2, multicenter, double-blind, randomized, placebo-controlled study of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination in South African adults aged 18-65 years. South Africa's first, second, and third waves of SARS-CoV-2 infections were respectively driven by the ancestral SARS-CoV-2 virus (wild type, WT), and SARS-CoV-2 Beta and Delta VoCs. VE against asymptomatic and symptomatic infection was 90.6% for WT, 6.7% for Beta and 77.1% for Delta. No cases of severe COVID-19 were documented ahead of unblinding. Safety was consistent with the interim analysis, with no new safety concerns identified. Notably, South Africa's Delta wave occurred ≥ 9 months after primary series vaccination, suggesting that primary series AZD1222 vaccination offers a good durability of protection, potentially due to an anamnestic response. Clinical trial identifier: CT.gov NCT04444674.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Koen AL, Izu A, Baillie V, et al. Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005). Vaccine. 2023. PMID: 37149443. doi:10.1016/j.vaccine.2023.04.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。